nodes	percent_of_prediction	percent_of_DWPC	metapath
Eletriptan—ABCB1—ovarian cancer	0.352	1	CbGaD
Eletriptan—ABCB1—Topotecan—ovarian cancer	0.0511	0.168	CbGbCtD
Eletriptan—ABCB1—Vinorelbine—ovarian cancer	0.036	0.119	CbGbCtD
Eletriptan—CYP2D6—Vinorelbine—ovarian cancer	0.0339	0.112	CbGbCtD
Eletriptan—CYP3A4—Topotecan—ovarian cancer	0.0306	0.101	CbGbCtD
Eletriptan—CYP2C9—Paclitaxel—ovarian cancer	0.0261	0.0858	CbGbCtD
Eletriptan—ABCB1—Paclitaxel—ovarian cancer	0.0253	0.0833	CbGbCtD
Eletriptan—CYP3A4—Vinorelbine—ovarian cancer	0.0216	0.071	CbGbCtD
Eletriptan—ABCB1—Docetaxel—ovarian cancer	0.0183	0.0602	CbGbCtD
Eletriptan—CYP3A4—Paclitaxel—ovarian cancer	0.0152	0.0499	CbGbCtD
Eletriptan—ABCB1—Doxorubicin—ovarian cancer	0.0136	0.0449	CbGbCtD
Eletriptan—CYP2D6—Doxorubicin—ovarian cancer	0.0129	0.0423	CbGbCtD
Eletriptan—CYP3A4—Docetaxel—ovarian cancer	0.011	0.0361	CbGbCtD
Eletriptan—CYP3A4—Doxorubicin—ovarian cancer	0.00817	0.0269	CbGbCtD
Eletriptan—HTR7—vein—ovarian cancer	0.00676	0.158	CbGeAlD
Eletriptan—HTR1E—myometrium—ovarian cancer	0.00365	0.0853	CbGeAlD
Eletriptan—PTGS1—oviduct—ovarian cancer	0.00287	0.0672	CbGeAlD
Eletriptan—HTR1E—female gonad—ovarian cancer	0.00193	0.0453	CbGeAlD
Eletriptan—HTR2B—myometrium—ovarian cancer	0.00155	0.0363	CbGeAlD
Eletriptan—HTR2B—uterine cervix—ovarian cancer	0.00121	0.0283	CbGeAlD
Eletriptan—HTR2B—decidua—ovarian cancer	0.00115	0.0269	CbGeAlD
Eletriptan—HTR2B—endometrium—ovarian cancer	0.00109	0.0256	CbGeAlD
Eletriptan—CYP2A6—vagina—ovarian cancer	0.00106	0.0249	CbGeAlD
Eletriptan—HTR7—epithelium—ovarian cancer	0.00104	0.0244	CbGeAlD
Eletriptan—HTR2B—uterus—ovarian cancer	0.00101	0.0236	CbGeAlD
Eletriptan—HTR1B—female reproductive system—ovarian cancer	0.00101	0.0235	CbGeAlD
Eletriptan—HTR1D—female reproductive system—ovarian cancer	0.000974	0.0228	CbGeAlD
Eletriptan—HTR2B—female reproductive system—ovarian cancer	0.000906	0.0212	CbGeAlD
Eletriptan—HTR7—gonad—ovarian cancer	0.000868	0.0203	CbGeAlD
Eletriptan—HTR2B—vagina—ovarian cancer	0.000819	0.0192	CbGeAlD
Eletriptan—HTR7—female reproductive system—ovarian cancer	0.000775	0.0181	CbGeAlD
Eletriptan—PTGS1—epithelium—ovarian cancer	0.000722	0.0169	CbGeAlD
Eletriptan—PTGS1—uterine cervix—ovarian cancer	0.000715	0.0167	CbGeAlD
Eletriptan—CYP2C19—vagina—ovarian cancer	0.000685	0.016	CbGeAlD
Eletriptan—PTGS1—endometrium—ovarian cancer	0.000647	0.0151	CbGeAlD
Eletriptan—HTR7—testis—ovarian cancer	0.000626	0.0146	CbGeAlD
Eletriptan—PTGS1—uterus—ovarian cancer	0.000596	0.014	CbGeAlD
Eletriptan—CYP2C9—female reproductive system—ovarian cancer	0.000587	0.0137	CbGeAlD
Eletriptan—ABCB1—myometrium—ovarian cancer	0.000544	0.0127	CbGeAlD
Eletriptan—PTGS1—female reproductive system—ovarian cancer	0.000536	0.0125	CbGeAlD
Eletriptan—HTR2B—lymph node—ovarian cancer	0.00053	0.0124	CbGeAlD
Eletriptan—ABCB1—embryo—ovarian cancer	0.000523	0.0122	CbGeAlD
Eletriptan—PTGS1—female gonad—ovarian cancer	0.000488	0.0114	CbGeAlD
Eletriptan—PTGS1—vagina—ovarian cancer	0.000485	0.0113	CbGeAlD
Eletriptan—CYP3A4—female reproductive system—ovarian cancer	0.000448	0.0105	CbGeAlD
Eletriptan—CYP2D6—female reproductive system—ovarian cancer	0.000441	0.0103	CbGeAlD
Eletriptan—PTGS1—testis—ovarian cancer	0.000433	0.0101	CbGeAlD
Eletriptan—ABCB1—epithelium—ovarian cancer	0.000427	0.00998	CbGeAlD
Eletriptan—ABCB1—uterine cervix—ovarian cancer	0.000423	0.0099	CbGeAlD
Eletriptan—ABCB1—decidua—ovarian cancer	0.000403	0.00943	CbGeAlD
Eletriptan—CYP2D6—female gonad—ovarian cancer	0.000401	0.00938	CbGeAlD
Eletriptan—ABCB1—endometrium—ovarian cancer	0.000383	0.00895	CbGeAlD
Eletriptan—CYP2D6—testis—ovarian cancer	0.000356	0.00832	CbGeAlD
Eletriptan—ABCB1—gonad—ovarian cancer	0.000355	0.0083	CbGeAlD
Eletriptan—ABCB1—uterus—ovarian cancer	0.000353	0.00825	CbGeAlD
Eletriptan—ABCB1—female reproductive system—ovarian cancer	0.000317	0.00742	CbGeAlD
Eletriptan—PTGS1—lymph node—ovarian cancer	0.000314	0.00734	CbGeAlD
Eletriptan—ABCB1—bone marrow—ovarian cancer	0.000299	0.007	CbGeAlD
Eletriptan—ABCB1—female gonad—ovarian cancer	0.000288	0.00675	CbGeAlD
Eletriptan—ABCB1—vagina—ovarian cancer	0.000287	0.00671	CbGeAlD
Eletriptan—ABCB1—testis—ovarian cancer	0.000256	0.00598	CbGeAlD
Eletriptan—Vomiting—Vinorelbine—ovarian cancer	0.000217	0.000724	CcSEcCtD
Eletriptan—Rash—Vinorelbine—ovarian cancer	0.000215	0.000718	CcSEcCtD
Eletriptan—Dermatitis—Vinorelbine—ovarian cancer	0.000215	0.000717	CcSEcCtD
Eletriptan—Abdominal distension—Doxorubicin—ovarian cancer	0.000215	0.000717	CcSEcCtD
Eletriptan—Hypotension—Paclitaxel—ovarian cancer	0.000214	0.000716	CcSEcCtD
Eletriptan—Headache—Vinorelbine—ovarian cancer	0.000213	0.000713	CcSEcCtD
Eletriptan—Syncope—Docetaxel—ovarian cancer	0.000213	0.000713	CcSEcCtD
Eletriptan—Asthma—Doxorubicin—ovarian cancer	0.000213	0.000712	CcSEcCtD
Eletriptan—Influenza—Doxorubicin—ovarian cancer	0.000213	0.000712	CcSEcCtD
Eletriptan—Dysphagia—Doxorubicin—ovarian cancer	0.000213	0.000712	CcSEcCtD
Eletriptan—Leukopenia—Docetaxel—ovarian cancer	0.000213	0.000712	CcSEcCtD
Eletriptan—Pollakiuria—Epirubicin—ovarian cancer	0.000213	0.000711	CcSEcCtD
Eletriptan—Palpitations—Docetaxel—ovarian cancer	0.00021	0.000703	CcSEcCtD
Eletriptan—Weight increased—Epirubicin—ovarian cancer	0.00021	0.000701	CcSEcCtD
Eletriptan—Loss of consciousness—Docetaxel—ovarian cancer	0.000209	0.000699	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000209	0.000698	CcSEcCtD
Eletriptan—Weight decreased—Epirubicin—ovarian cancer	0.000208	0.000697	CcSEcCtD
Eletriptan—Hyperglycaemia—Epirubicin—ovarian cancer	0.000208	0.000694	CcSEcCtD
Eletriptan—Cough—Docetaxel—ovarian cancer	0.000208	0.000694	CcSEcCtD
Eletriptan—Angina pectoris—Doxorubicin—ovarian cancer	0.000208	0.000694	CcSEcCtD
Eletriptan—Insomnia—Paclitaxel—ovarian cancer	0.000207	0.000693	CcSEcCtD
Eletriptan—Convulsion—Docetaxel—ovarian cancer	0.000206	0.000689	CcSEcCtD
Eletriptan—Paraesthesia—Paclitaxel—ovarian cancer	0.000206	0.000688	CcSEcCtD
Eletriptan—Hypertension—Docetaxel—ovarian cancer	0.000206	0.000687	CcSEcCtD
Eletriptan—Drowsiness—Epirubicin—ovarian cancer	0.000205	0.000686	CcSEcCtD
Eletriptan—Bronchitis—Doxorubicin—ovarian cancer	0.000205	0.000685	CcSEcCtD
Eletriptan—Dyspnoea—Paclitaxel—ovarian cancer	0.000204	0.000683	CcSEcCtD
Eletriptan—Somnolence—Paclitaxel—ovarian cancer	0.000204	0.000681	CcSEcCtD
Eletriptan—Arthralgia—Docetaxel—ovarian cancer	0.000203	0.000677	CcSEcCtD
Eletriptan—Myalgia—Docetaxel—ovarian cancer	0.000203	0.000677	CcSEcCtD
Eletriptan—Nausea—Vinorelbine—ovarian cancer	0.000202	0.000676	CcSEcCtD
Eletriptan—Dyspepsia—Paclitaxel—ovarian cancer	0.000202	0.000674	CcSEcCtD
Eletriptan—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000201	0.000673	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000201	0.000672	CcSEcCtD
Eletriptan—Stomatitis—Epirubicin—ovarian cancer	0.0002	0.000669	CcSEcCtD
Eletriptan—Conjunctivitis—Epirubicin—ovarian cancer	0.0002	0.000667	CcSEcCtD
Eletriptan—Decreased appetite—Paclitaxel—ovarian cancer	0.000199	0.000666	CcSEcCtD
Eletriptan—Dry mouth—Docetaxel—ovarian cancer	0.000198	0.000662	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000198	0.000661	CcSEcCtD
Eletriptan—Fatigue—Paclitaxel—ovarian cancer	0.000198	0.00066	CcSEcCtD
Eletriptan—Sweating—Epirubicin—ovarian cancer	0.000197	0.000658	CcSEcCtD
Eletriptan—Pollakiuria—Doxorubicin—ovarian cancer	0.000197	0.000658	CcSEcCtD
Eletriptan—Pain—Paclitaxel—ovarian cancer	0.000196	0.000655	CcSEcCtD
Eletriptan—Constipation—Paclitaxel—ovarian cancer	0.000196	0.000655	CcSEcCtD
Eletriptan—Confusional state—Docetaxel—ovarian cancer	0.000196	0.000654	CcSEcCtD
Eletriptan—Oedema—Docetaxel—ovarian cancer	0.000194	0.000649	CcSEcCtD
Eletriptan—Weight increased—Doxorubicin—ovarian cancer	0.000194	0.000648	CcSEcCtD
Eletriptan—Epistaxis—Epirubicin—ovarian cancer	0.000194	0.000647	CcSEcCtD
Eletriptan—Weight decreased—Doxorubicin—ovarian cancer	0.000193	0.000644	CcSEcCtD
Eletriptan—Sinusitis—Epirubicin—ovarian cancer	0.000193	0.000644	CcSEcCtD
Eletriptan—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000192	0.000643	CcSEcCtD
Eletriptan—Shock—Docetaxel—ovarian cancer	0.000191	0.000639	CcSEcCtD
Eletriptan—Nervous system disorder—Docetaxel—ovarian cancer	0.000191	0.000637	CcSEcCtD
Eletriptan—Drowsiness—Doxorubicin—ovarian cancer	0.00019	0.000635	CcSEcCtD
Eletriptan—Tachycardia—Docetaxel—ovarian cancer	0.00019	0.000633	CcSEcCtD
Eletriptan—Feeling abnormal—Paclitaxel—ovarian cancer	0.000189	0.000631	CcSEcCtD
Eletriptan—Skin disorder—Docetaxel—ovarian cancer	0.000189	0.00063	CcSEcCtD
Eletriptan—Bradycardia—Epirubicin—ovarian cancer	0.000188	0.000627	CcSEcCtD
Eletriptan—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000187	0.000626	CcSEcCtD
Eletriptan—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000186	0.000623	CcSEcCtD
Eletriptan—ABCB1—lymph node—ovarian cancer	0.000185	0.00434	CbGeAlD
Eletriptan—Stomatitis—Doxorubicin—ovarian cancer	0.000185	0.000619	CcSEcCtD
Eletriptan—Anorexia—Docetaxel—ovarian cancer	0.000185	0.000619	CcSEcCtD
Eletriptan—Rhinitis—Epirubicin—ovarian cancer	0.000185	0.000618	CcSEcCtD
Eletriptan—Conjunctivitis—Doxorubicin—ovarian cancer	0.000185	0.000617	CcSEcCtD
Eletriptan—Hypoaesthesia—Epirubicin—ovarian cancer	0.000184	0.000613	CcSEcCtD
Eletriptan—Pharyngitis—Epirubicin—ovarian cancer	0.000183	0.000612	CcSEcCtD
Eletriptan—Sweating—Doxorubicin—ovarian cancer	0.000182	0.000609	CcSEcCtD
Eletriptan—Urinary tract disorder—Epirubicin—ovarian cancer	0.000182	0.000609	CcSEcCtD
Eletriptan—Urticaria—Paclitaxel—ovarian cancer	0.000182	0.000608	CcSEcCtD
Eletriptan—Oedema peripheral—Epirubicin—ovarian cancer	0.000182	0.000607	CcSEcCtD
Eletriptan—Hypotension—Docetaxel—ovarian cancer	0.000182	0.000607	CcSEcCtD
Eletriptan—Abdominal pain—Paclitaxel—ovarian cancer	0.000181	0.000605	CcSEcCtD
Eletriptan—Body temperature increased—Paclitaxel—ovarian cancer	0.000181	0.000605	CcSEcCtD
Eletriptan—Urethral disorder—Epirubicin—ovarian cancer	0.000181	0.000604	CcSEcCtD
Eletriptan—Epistaxis—Doxorubicin—ovarian cancer	0.000179	0.000599	CcSEcCtD
Eletriptan—Sinusitis—Doxorubicin—ovarian cancer	0.000178	0.000596	CcSEcCtD
Eletriptan—Visual impairment—Epirubicin—ovarian cancer	0.000178	0.000594	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000177	0.000591	CcSEcCtD
Eletriptan—Insomnia—Docetaxel—ovarian cancer	0.000176	0.000587	CcSEcCtD
Eletriptan—Paraesthesia—Docetaxel—ovarian cancer	0.000174	0.000583	CcSEcCtD
Eletriptan—Bradycardia—Doxorubicin—ovarian cancer	0.000174	0.00058	CcSEcCtD
Eletriptan—Dyspnoea—Docetaxel—ovarian cancer	0.000173	0.000579	CcSEcCtD
Eletriptan—Somnolence—Docetaxel—ovarian cancer	0.000173	0.000577	CcSEcCtD
Eletriptan—Tinnitus—Epirubicin—ovarian cancer	0.000172	0.000575	CcSEcCtD
Eletriptan—Flushing—Epirubicin—ovarian cancer	0.000171	0.000572	CcSEcCtD
Eletriptan—Rhinitis—Doxorubicin—ovarian cancer	0.000171	0.000572	CcSEcCtD
Eletriptan—Dyspepsia—Docetaxel—ovarian cancer	0.000171	0.000571	CcSEcCtD
Eletriptan—Hypoaesthesia—Doxorubicin—ovarian cancer	0.00017	0.000567	CcSEcCtD
Eletriptan—Pharyngitis—Doxorubicin—ovarian cancer	0.000169	0.000566	CcSEcCtD
Eletriptan—Decreased appetite—Docetaxel—ovarian cancer	0.000169	0.000564	CcSEcCtD
Eletriptan—Hypersensitivity—Paclitaxel—ovarian cancer	0.000169	0.000564	CcSEcCtD
Eletriptan—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000169	0.000563	CcSEcCtD
Eletriptan—Oedema peripheral—Doxorubicin—ovarian cancer	0.000168	0.000562	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000168	0.00056	CcSEcCtD
Eletriptan—Fatigue—Docetaxel—ovarian cancer	0.000167	0.00056	CcSEcCtD
Eletriptan—Urethral disorder—Doxorubicin—ovarian cancer	0.000167	0.000559	CcSEcCtD
Eletriptan—Immune system disorder—Epirubicin—ovarian cancer	0.000167	0.000557	CcSEcCtD
Eletriptan—Pain—Docetaxel—ovarian cancer	0.000166	0.000555	CcSEcCtD
Eletriptan—Constipation—Docetaxel—ovarian cancer	0.000166	0.000555	CcSEcCtD
Eletriptan—Chills—Epirubicin—ovarian cancer	0.000165	0.000553	CcSEcCtD
Eletriptan—Arrhythmia—Epirubicin—ovarian cancer	0.000165	0.00055	CcSEcCtD
Eletriptan—Visual impairment—Doxorubicin—ovarian cancer	0.000164	0.000549	CcSEcCtD
Eletriptan—Asthenia—Paclitaxel—ovarian cancer	0.000164	0.000549	CcSEcCtD
Eletriptan—Alopecia—Epirubicin—ovarian cancer	0.000163	0.000545	CcSEcCtD
Eletriptan—Pruritus—Paclitaxel—ovarian cancer	0.000162	0.000542	CcSEcCtD
Eletriptan—Feeling abnormal—Docetaxel—ovarian cancer	0.00016	0.000535	CcSEcCtD
Eletriptan—Tinnitus—Doxorubicin—ovarian cancer	0.000159	0.000532	CcSEcCtD
Eletriptan—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000159	0.000531	CcSEcCtD
Eletriptan—Flushing—Doxorubicin—ovarian cancer	0.000158	0.000529	CcSEcCtD
Eletriptan—Flatulence—Epirubicin—ovarian cancer	0.000158	0.000529	CcSEcCtD
Eletriptan—Tension—Epirubicin—ovarian cancer	0.000158	0.000526	CcSEcCtD
Eletriptan—Dysgeusia—Epirubicin—ovarian cancer	0.000157	0.000525	CcSEcCtD
Eletriptan—Diarrhoea—Paclitaxel—ovarian cancer	0.000157	0.000524	CcSEcCtD
Eletriptan—Nervousness—Epirubicin—ovarian cancer	0.000156	0.000521	CcSEcCtD
Eletriptan—Back pain—Epirubicin—ovarian cancer	0.000155	0.000519	CcSEcCtD
Eletriptan—Muscle spasms—Epirubicin—ovarian cancer	0.000154	0.000516	CcSEcCtD
Eletriptan—Immune system disorder—Doxorubicin—ovarian cancer	0.000154	0.000515	CcSEcCtD
Eletriptan—Body temperature increased—Docetaxel—ovarian cancer	0.000154	0.000513	CcSEcCtD
Eletriptan—Abdominal pain—Docetaxel—ovarian cancer	0.000154	0.000513	CcSEcCtD
Eletriptan—Chills—Doxorubicin—ovarian cancer	0.000153	0.000512	CcSEcCtD
Eletriptan—Arrhythmia—Doxorubicin—ovarian cancer	0.000152	0.000509	CcSEcCtD
Eletriptan—Dizziness—Paclitaxel—ovarian cancer	0.000152	0.000506	CcSEcCtD
Eletriptan—Alopecia—Doxorubicin—ovarian cancer	0.000151	0.000504	CcSEcCtD
Eletriptan—Ill-defined disorder—Epirubicin—ovarian cancer	0.000149	0.000498	CcSEcCtD
Eletriptan—Anaemia—Epirubicin—ovarian cancer	0.000148	0.000496	CcSEcCtD
Eletriptan—Agitation—Epirubicin—ovarian cancer	0.000148	0.000493	CcSEcCtD
Eletriptan—Flatulence—Doxorubicin—ovarian cancer	0.000146	0.000489	CcSEcCtD
Eletriptan—Tension—Doxorubicin—ovarian cancer	0.000146	0.000487	CcSEcCtD
Eletriptan—Vomiting—Paclitaxel—ovarian cancer	0.000146	0.000487	CcSEcCtD
Eletriptan—Dysgeusia—Doxorubicin—ovarian cancer	0.000145	0.000486	CcSEcCtD
Eletriptan—Malaise—Epirubicin—ovarian cancer	0.000145	0.000484	CcSEcCtD
Eletriptan—Rash—Paclitaxel—ovarian cancer	0.000145	0.000483	CcSEcCtD
Eletriptan—Dermatitis—Paclitaxel—ovarian cancer	0.000144	0.000482	CcSEcCtD
Eletriptan—Nervousness—Doxorubicin—ovarian cancer	0.000144	0.000482	CcSEcCtD
Eletriptan—Vertigo—Epirubicin—ovarian cancer	0.000144	0.000482	CcSEcCtD
Eletriptan—Syncope—Epirubicin—ovarian cancer	0.000144	0.000481	CcSEcCtD
Eletriptan—Leukopenia—Epirubicin—ovarian cancer	0.000144	0.00048	CcSEcCtD
Eletriptan—Back pain—Doxorubicin—ovarian cancer	0.000144	0.00048	CcSEcCtD
Eletriptan—Headache—Paclitaxel—ovarian cancer	0.000144	0.00048	CcSEcCtD
Eletriptan—Hypersensitivity—Docetaxel—ovarian cancer	0.000143	0.000478	CcSEcCtD
Eletriptan—Muscle spasms—Doxorubicin—ovarian cancer	0.000143	0.000477	CcSEcCtD
Eletriptan—Palpitations—Epirubicin—ovarian cancer	0.000142	0.000474	CcSEcCtD
Eletriptan—Loss of consciousness—Epirubicin—ovarian cancer	0.000141	0.000471	CcSEcCtD
Eletriptan—Cough—Epirubicin—ovarian cancer	0.00014	0.000468	CcSEcCtD
Eletriptan—Asthenia—Docetaxel—ovarian cancer	0.000139	0.000466	CcSEcCtD
Eletriptan—Convulsion—Epirubicin—ovarian cancer	0.000139	0.000465	CcSEcCtD
Eletriptan—Hypertension—Epirubicin—ovarian cancer	0.000139	0.000463	CcSEcCtD
Eletriptan—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000138	0.000461	CcSEcCtD
Eletriptan—Pruritus—Docetaxel—ovarian cancer	0.000137	0.000459	CcSEcCtD
Eletriptan—Anaemia—Doxorubicin—ovarian cancer	0.000137	0.000459	CcSEcCtD
Eletriptan—Arthralgia—Epirubicin—ovarian cancer	0.000137	0.000457	CcSEcCtD
Eletriptan—Myalgia—Epirubicin—ovarian cancer	0.000137	0.000457	CcSEcCtD
Eletriptan—Agitation—Doxorubicin—ovarian cancer	0.000137	0.000456	CcSEcCtD
Eletriptan—Anxiety—Epirubicin—ovarian cancer	0.000136	0.000455	CcSEcCtD
Eletriptan—Nausea—Paclitaxel—ovarian cancer	0.000136	0.000455	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000136	0.000454	CcSEcCtD
Eletriptan—Discomfort—Epirubicin—ovarian cancer	0.000135	0.000451	CcSEcCtD
Eletriptan—Malaise—Doxorubicin—ovarian cancer	0.000134	0.000448	CcSEcCtD
Eletriptan—Dry mouth—Epirubicin—ovarian cancer	0.000134	0.000447	CcSEcCtD
Eletriptan—Vertigo—Doxorubicin—ovarian cancer	0.000133	0.000446	CcSEcCtD
Eletriptan—Syncope—Doxorubicin—ovarian cancer	0.000133	0.000445	CcSEcCtD
Eletriptan—Leukopenia—Doxorubicin—ovarian cancer	0.000133	0.000444	CcSEcCtD
Eletriptan—Diarrhoea—Docetaxel—ovarian cancer	0.000133	0.000444	CcSEcCtD
Eletriptan—Confusional state—Epirubicin—ovarian cancer	0.000132	0.000441	CcSEcCtD
Eletriptan—Palpitations—Doxorubicin—ovarian cancer	0.000131	0.000439	CcSEcCtD
Eletriptan—Oedema—Epirubicin—ovarian cancer	0.000131	0.000438	CcSEcCtD
Eletriptan—Loss of consciousness—Doxorubicin—ovarian cancer	0.000131	0.000436	CcSEcCtD
Eletriptan—Cough—Doxorubicin—ovarian cancer	0.00013	0.000433	CcSEcCtD
Eletriptan—Shock—Epirubicin—ovarian cancer	0.000129	0.000431	CcSEcCtD
Eletriptan—Convulsion—Doxorubicin—ovarian cancer	0.000129	0.00043	CcSEcCtD
Eletriptan—Nervous system disorder—Epirubicin—ovarian cancer	0.000129	0.000429	CcSEcCtD
Eletriptan—Dizziness—Docetaxel—ovarian cancer	0.000128	0.000429	CcSEcCtD
Eletriptan—Hypertension—Doxorubicin—ovarian cancer	0.000128	0.000429	CcSEcCtD
Eletriptan—Tachycardia—Epirubicin—ovarian cancer	0.000128	0.000427	CcSEcCtD
Eletriptan—Skin disorder—Epirubicin—ovarian cancer	0.000127	0.000425	CcSEcCtD
Eletriptan—Hyperhidrosis—Epirubicin—ovarian cancer	0.000127	0.000423	CcSEcCtD
Eletriptan—Arthralgia—Doxorubicin—ovarian cancer	0.000126	0.000423	CcSEcCtD
Eletriptan—Myalgia—Doxorubicin—ovarian cancer	0.000126	0.000423	CcSEcCtD
Eletriptan—Anxiety—Doxorubicin—ovarian cancer	0.000126	0.000421	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000126	0.00042	CcSEcCtD
Eletriptan—Discomfort—Doxorubicin—ovarian cancer	0.000125	0.000417	CcSEcCtD
Eletriptan—Anorexia—Epirubicin—ovarian cancer	0.000125	0.000417	CcSEcCtD
Eletriptan—Dry mouth—Doxorubicin—ovarian cancer	0.000124	0.000413	CcSEcCtD
Eletriptan—Vomiting—Docetaxel—ovarian cancer	0.000124	0.000413	CcSEcCtD
Eletriptan—Rash—Docetaxel—ovarian cancer	0.000122	0.000409	CcSEcCtD
Eletriptan—Hypotension—Epirubicin—ovarian cancer	0.000122	0.000409	CcSEcCtD
Eletriptan—Dermatitis—Docetaxel—ovarian cancer	0.000122	0.000409	CcSEcCtD
Eletriptan—Confusional state—Doxorubicin—ovarian cancer	0.000122	0.000408	CcSEcCtD
Eletriptan—Headache—Docetaxel—ovarian cancer	0.000122	0.000407	CcSEcCtD
Eletriptan—Oedema—Doxorubicin—ovarian cancer	0.000121	0.000405	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000119	0.000399	CcSEcCtD
Eletriptan—Shock—Doxorubicin—ovarian cancer	0.000119	0.000399	CcSEcCtD
Eletriptan—Nervous system disorder—Doxorubicin—ovarian cancer	0.000119	0.000397	CcSEcCtD
Eletriptan—Insomnia—Epirubicin—ovarian cancer	0.000119	0.000396	CcSEcCtD
Eletriptan—Tachycardia—Doxorubicin—ovarian cancer	0.000118	0.000395	CcSEcCtD
Eletriptan—Skin disorder—Doxorubicin—ovarian cancer	0.000118	0.000393	CcSEcCtD
Eletriptan—Paraesthesia—Epirubicin—ovarian cancer	0.000118	0.000393	CcSEcCtD
Eletriptan—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000117	0.000392	CcSEcCtD
Eletriptan—Dyspnoea—Epirubicin—ovarian cancer	0.000117	0.00039	CcSEcCtD
Eletriptan—Somnolence—Epirubicin—ovarian cancer	0.000116	0.000389	CcSEcCtD
Eletriptan—Anorexia—Doxorubicin—ovarian cancer	0.000116	0.000386	CcSEcCtD
Eletriptan—Nausea—Docetaxel—ovarian cancer	0.000115	0.000386	CcSEcCtD
Eletriptan—Dyspepsia—Epirubicin—ovarian cancer	0.000115	0.000385	CcSEcCtD
Eletriptan—Decreased appetite—Epirubicin—ovarian cancer	0.000114	0.000381	CcSEcCtD
Eletriptan—Hypotension—Doxorubicin—ovarian cancer	0.000113	0.000379	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000113	0.000378	CcSEcCtD
Eletriptan—Fatigue—Epirubicin—ovarian cancer	0.000113	0.000377	CcSEcCtD
Eletriptan—Pain—Epirubicin—ovarian cancer	0.000112	0.000374	CcSEcCtD
Eletriptan—Constipation—Epirubicin—ovarian cancer	0.000112	0.000374	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.00011	0.000369	CcSEcCtD
Eletriptan—Insomnia—Doxorubicin—ovarian cancer	0.00011	0.000366	CcSEcCtD
Eletriptan—Paraesthesia—Doxorubicin—ovarian cancer	0.000109	0.000364	CcSEcCtD
Eletriptan—Dyspnoea—Doxorubicin—ovarian cancer	0.000108	0.000361	CcSEcCtD
Eletriptan—Feeling abnormal—Epirubicin—ovarian cancer	0.000108	0.000361	CcSEcCtD
Eletriptan—Somnolence—Doxorubicin—ovarian cancer	0.000108	0.00036	CcSEcCtD
Eletriptan—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000107	0.000358	CcSEcCtD
Eletriptan—Dyspepsia—Doxorubicin—ovarian cancer	0.000107	0.000357	CcSEcCtD
Eletriptan—Decreased appetite—Doxorubicin—ovarian cancer	0.000105	0.000352	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000105	0.00035	CcSEcCtD
Eletriptan—Fatigue—Doxorubicin—ovarian cancer	0.000105	0.000349	CcSEcCtD
Eletriptan—Urticaria—Epirubicin—ovarian cancer	0.000104	0.000348	CcSEcCtD
Eletriptan—Pain—Doxorubicin—ovarian cancer	0.000104	0.000346	CcSEcCtD
Eletriptan—Constipation—Doxorubicin—ovarian cancer	0.000104	0.000346	CcSEcCtD
Eletriptan—Body temperature increased—Epirubicin—ovarian cancer	0.000104	0.000346	CcSEcCtD
Eletriptan—Abdominal pain—Epirubicin—ovarian cancer	0.000104	0.000346	CcSEcCtD
Eletriptan—Feeling abnormal—Doxorubicin—ovarian cancer	9.99e-05	0.000334	CcSEcCtD
Eletriptan—Gastrointestinal pain—Doxorubicin—ovarian cancer	9.91e-05	0.000331	CcSEcCtD
Eletriptan—Hypersensitivity—Epirubicin—ovarian cancer	9.65e-05	0.000323	CcSEcCtD
Eletriptan—Urticaria—Doxorubicin—ovarian cancer	9.63e-05	0.000322	CcSEcCtD
Eletriptan—Body temperature increased—Doxorubicin—ovarian cancer	9.58e-05	0.00032	CcSEcCtD
Eletriptan—Abdominal pain—Doxorubicin—ovarian cancer	9.58e-05	0.00032	CcSEcCtD
Eletriptan—Asthenia—Epirubicin—ovarian cancer	9.4e-05	0.000314	CcSEcCtD
Eletriptan—Pruritus—Epirubicin—ovarian cancer	9.27e-05	0.00031	CcSEcCtD
Eletriptan—Diarrhoea—Epirubicin—ovarian cancer	8.97e-05	0.0003	CcSEcCtD
Eletriptan—Hypersensitivity—Doxorubicin—ovarian cancer	8.93e-05	0.000298	CcSEcCtD
Eletriptan—Asthenia—Doxorubicin—ovarian cancer	8.7e-05	0.000291	CcSEcCtD
Eletriptan—Dizziness—Epirubicin—ovarian cancer	8.67e-05	0.00029	CcSEcCtD
Eletriptan—Pruritus—Doxorubicin—ovarian cancer	8.58e-05	0.000287	CcSEcCtD
Eletriptan—Vomiting—Epirubicin—ovarian cancer	8.33e-05	0.000278	CcSEcCtD
Eletriptan—Diarrhoea—Doxorubicin—ovarian cancer	8.3e-05	0.000277	CcSEcCtD
Eletriptan—Rash—Epirubicin—ovarian cancer	8.26e-05	0.000276	CcSEcCtD
Eletriptan—Dermatitis—Epirubicin—ovarian cancer	8.25e-05	0.000276	CcSEcCtD
Eletriptan—Headache—Epirubicin—ovarian cancer	8.21e-05	0.000274	CcSEcCtD
Eletriptan—Dizziness—Doxorubicin—ovarian cancer	8.02e-05	0.000268	CcSEcCtD
Eletriptan—Nausea—Epirubicin—ovarian cancer	7.78e-05	0.00026	CcSEcCtD
Eletriptan—Vomiting—Doxorubicin—ovarian cancer	7.71e-05	0.000258	CcSEcCtD
Eletriptan—Rash—Doxorubicin—ovarian cancer	7.64e-05	0.000255	CcSEcCtD
Eletriptan—Dermatitis—Doxorubicin—ovarian cancer	7.64e-05	0.000255	CcSEcCtD
Eletriptan—Headache—Doxorubicin—ovarian cancer	7.6e-05	0.000254	CcSEcCtD
Eletriptan—Nausea—Doxorubicin—ovarian cancer	7.2e-05	0.000241	CcSEcCtD
Eletriptan—HTR1A—Signaling Pathways—CAV1—ovarian cancer	5.38e-07	0.000315	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CYP1B1—ovarian cancer	5.37e-07	0.000314	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CG—ovarian cancer	5.35e-07	0.000313	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—MYC—ovarian cancer	5.33e-07	0.000312	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CD—ovarian cancer	5.31e-07	0.000311	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—SLC2A1—ovarian cancer	5.28e-07	0.000309	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—PIK3CA—ovarian cancer	5.26e-07	0.000308	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—PIK3CA—ovarian cancer	5.23e-07	0.000306	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—SLC2A1—ovarian cancer	5.23e-07	0.000306	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—KRAS—ovarian cancer	5.23e-07	0.000306	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—MAPK1—ovarian cancer	5.22e-07	0.000305	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—EGFR—ovarian cancer	5.22e-07	0.000305	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—KRAS—ovarian cancer	5.2e-07	0.000304	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—PIK3CA—ovarian cancer	5.2e-07	0.000304	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—ESR1—ovarian cancer	5.19e-07	0.000303	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—ERBB2—ovarian cancer	5.14e-07	0.000301	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.12e-07	0.0003	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—ERBB2—ovarian cancer	5.1e-07	0.000299	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL6ST—ovarian cancer	5.1e-07	0.000298	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—PIK3CA—ovarian cancer	5.09e-07	0.000298	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MTOR—ovarian cancer	5.07e-07	0.000297	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PIK3CB—ovarian cancer	5.07e-07	0.000297	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CYP1B1—ovarian cancer	5.06e-07	0.000296	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MTOR—ovarian cancer	5.04e-07	0.000295	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PIK3CB—ovarian cancer	5.04e-07	0.000295	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CYP1B1—ovarian cancer	5.01e-07	0.000293	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—ERBB2—ovarian cancer	5e-07	0.000292	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CD—ovarian cancer	4.98e-07	0.000291	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PIK3CB—ovarian cancer	4.93e-07	0.000288	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MTOR—ovarian cancer	4.93e-07	0.000288	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—KRAS—ovarian cancer	4.93e-07	0.000288	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—APC—ovarian cancer	4.9e-07	0.000287	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CG—ovarian cancer	4.9e-07	0.000287	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—NRAS—ovarian cancer	4.9e-07	0.000287	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	4.88e-07	0.000285	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CXCL8—ovarian cancer	4.87e-07	0.000285	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.85e-07	0.000284	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—HRAS—ovarian cancer	4.84e-07	0.000283	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CXCL8—ovarian cancer	4.84e-07	0.000283	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—HRAS—ovarian cancer	4.81e-07	0.000281	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—PIK3CA—ovarian cancer	4.8e-07	0.000281	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—PIK3CA—ovarian cancer	4.78e-07	0.00028	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PPP2R1A—ovarian cancer	4.76e-07	0.000279	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CDKN1B—ovarian cancer	4.76e-07	0.000278	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CXCL8—ovarian cancer	4.74e-07	0.000277	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CDKN1B—ovarian cancer	4.73e-07	0.000276	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—HRAS—ovarian cancer	4.71e-07	0.000275	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CD—ovarian cancer	4.71e-07	0.000275	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—AKT1—ovarian cancer	4.71e-07	0.000275	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—MAPK3—ovarian cancer	4.7e-07	0.000275	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—ERBB2—ovarian cancer	4.69e-07	0.000275	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—AKT1—ovarian cancer	4.68e-07	0.000273	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CASP3—ovarian cancer	4.66e-07	0.000273	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IL2—ovarian cancer	4.66e-07	0.000272	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—TP53—ovarian cancer	4.64e-07	0.000272	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MTOR—ovarian cancer	4.63e-07	0.000271	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CB—ovarian cancer	4.63e-07	0.000271	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—IL6—ovarian cancer	4.63e-07	0.000271	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CASP3—ovarian cancer	4.63e-07	0.000271	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CDKN1B—ovarian cancer	4.63e-07	0.000271	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL2—ovarian cancer	4.63e-07	0.000271	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—IL6—ovarian cancer	4.6e-07	0.000269	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—AKT1—ovarian cancer	4.58e-07	0.000268	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCND1—ovarian cancer	4.54e-07	0.000265	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CASP3—ovarian cancer	4.54e-07	0.000265	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ABCB1—ovarian cancer	4.53e-07	0.000265	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL2—ovarian cancer	4.53e-07	0.000265	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—PIK3CA—ovarian cancer	4.53e-07	0.000265	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCND1—ovarian cancer	4.51e-07	0.000264	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—IL6—ovarian cancer	4.51e-07	0.000264	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CTNNB1—ovarian cancer	4.49e-07	0.000263	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	4.49e-07	0.000262	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—MAPK1—ovarian cancer	4.47e-07	0.000261	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—EGFR—ovarian cancer	4.47e-07	0.000261	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CTNNB1—ovarian cancer	4.47e-07	0.000261	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—YAP1—ovarian cancer	4.45e-07	0.000261	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CXCL8—ovarian cancer	4.45e-07	0.00026	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—TYMS—ovarian cancer	4.45e-07	0.00026	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	4.45e-07	0.00026	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—HRAS—ovarian cancer	4.44e-07	0.00026	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.43e-07	0.000259	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—HRAS—ovarian cancer	4.42e-07	0.000259	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCND1—ovarian cancer	4.41e-07	0.000258	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MMP9—ovarian cancer	4.41e-07	0.000258	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—TP53—ovarian cancer	4.38e-07	0.000256	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PTEN—ovarian cancer	4.38e-07	0.000256	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MMP9—ovarian cancer	4.38e-07	0.000256	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CTNNB1—ovarian cancer	4.37e-07	0.000256	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PTEN—ovarian cancer	4.35e-07	0.000255	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CDKN1B—ovarian cancer	4.35e-07	0.000254	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—TYMS—ovarian cancer	4.34e-07	0.000254	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CB—ovarian cancer	4.34e-07	0.000254	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CD—ovarian cancer	4.31e-07	0.000252	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—AKT1—ovarian cancer	4.3e-07	0.000252	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MMP9—ovarian cancer	4.29e-07	0.000251	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—AKT1—ovarian cancer	4.27e-07	0.00025	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—PIK3CA—ovarian cancer	4.27e-07	0.00025	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PTEN—ovarian cancer	4.26e-07	0.000249	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CASP3—ovarian cancer	4.26e-07	0.000249	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL2—ovarian cancer	4.25e-07	0.000249	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—IL6—ovarian cancer	4.25e-07	0.000249	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—AKT1—ovarian cancer	4.25e-07	0.000248	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—IL6—ovarian cancer	4.23e-07	0.000248	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—KRAS—ovarian cancer	4.22e-07	0.000247	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—HRAS—ovarian cancer	4.19e-07	0.000245	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ABCB1—ovarian cancer	4.17e-07	0.000244	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—AKT1—ovarian cancer	4.16e-07	0.000243	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCND1—ovarian cancer	4.15e-07	0.000243	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ABCB1—ovarian cancer	4.13e-07	0.000242	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CTNNB1—ovarian cancer	4.11e-07	0.00024	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CB—ovarian cancer	4.1e-07	0.00024	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—TYMS—ovarian cancer	4.09e-07	0.000239	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—TYMS—ovarian cancer	4.06e-07	0.000237	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MMP9—ovarian cancer	4.03e-07	0.000236	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—IL6—ovarian cancer	4.01e-07	0.000235	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PTEN—ovarian cancer	4e-07	0.000234	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—VEGFA—ovarian cancer	3.96e-07	0.000231	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—VEGFA—ovarian cancer	3.93e-07	0.00023	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—AKT1—ovarian cancer	3.92e-07	0.000229	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—STAT3—ovarian cancer	3.92e-07	0.000229	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—NRAS—ovarian cancer	3.91e-07	0.000229	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—AKT1—ovarian cancer	3.91e-07	0.000228	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—STAT3—ovarian cancer	3.89e-07	0.000228	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—NRAS—ovarian cancer	3.88e-07	0.000227	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—PIK3CA—ovarian cancer	3.88e-07	0.000227	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—VEGFA—ovarian cancer	3.85e-07	0.000225	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—STAT3—ovarian cancer	3.81e-07	0.000223	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—ERBB2—ovarian cancer	3.81e-07	0.000223	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—NRAS—ovarian cancer	3.8e-07	0.000222	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CB—ovarian cancer	3.76e-07	0.00022	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MTOR—ovarian cancer	3.76e-07	0.00022	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTEN—ovarian cancer	3.75e-07	0.000219	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MAPK3—ovarian cancer	3.74e-07	0.000219	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MAPK3—ovarian cancer	3.72e-07	0.000218	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—AKT1—ovarian cancer	3.7e-07	0.000216	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MAPK3—ovarian cancer	3.64e-07	0.000213	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MYC—ovarian cancer	3.64e-07	0.000213	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—FASN—ovarian cancer	3.63e-07	0.000212	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MYC—ovarian cancer	3.62e-07	0.000212	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—VEGFA—ovarian cancer	3.62e-07	0.000212	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CXCL8—ovarian cancer	3.61e-07	0.000211	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—HRAS—ovarian cancer	3.59e-07	0.00021	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CAV1—ovarian cancer	3.58e-07	0.00021	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—STAT3—ovarian cancer	3.58e-07	0.000209	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3.57e-07	0.000209	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—NRAS—ovarian cancer	3.57e-07	0.000209	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MAPK1—ovarian cancer	3.56e-07	0.000208	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—EGFR—ovarian cancer	3.56e-07	0.000208	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTEN—ovarian cancer	3.55e-07	0.000207	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MYC—ovarian cancer	3.54e-07	0.000207	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MAPK1—ovarian cancer	3.54e-07	0.000207	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—EGFR—ovarian cancer	3.54e-07	0.000207	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CDKN1B—ovarian cancer	3.53e-07	0.000206	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CAV1—ovarian cancer	3.5e-07	0.000205	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—AKT1—ovarian cancer	3.49e-07	0.000204	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MAPK1—ovarian cancer	3.46e-07	0.000203	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—EGFR—ovarian cancer	3.46e-07	0.000203	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CASP3—ovarian cancer	3.46e-07	0.000202	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL2—ovarian cancer	3.45e-07	0.000202	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—SLC2A1—ovarian cancer	3.45e-07	0.000202	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—IL6—ovarian cancer	3.43e-07	0.000201	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.42e-07	0.0002	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MAPK3—ovarian cancer	3.42e-07	0.0002	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—KRAS—ovarian cancer	3.36e-07	0.000197	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCND1—ovarian cancer	3.36e-07	0.000197	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—KRAS—ovarian cancer	3.34e-07	0.000195	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CTNNB1—ovarian cancer	3.33e-07	0.000195	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MYC—ovarian cancer	3.33e-07	0.000195	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP1B1—ovarian cancer	3.31e-07	0.000193	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CAV1—ovarian cancer	3.3e-07	0.000193	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—KRAS—ovarian cancer	3.27e-07	0.000191	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CAV1—ovarian cancer	3.27e-07	0.000191	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MMP9—ovarian cancer	3.27e-07	0.000191	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CG—ovarian cancer	3.26e-07	0.000191	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MAPK1—ovarian cancer	3.25e-07	0.00019	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—EGFR—ovarian cancer	3.25e-07	0.00019	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PTEN—ovarian cancer	3.25e-07	0.00019	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CG—ovarian cancer	3.19e-07	0.000186	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—AKT1—ovarian cancer	3.17e-07	0.000185	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.12e-07	0.000183	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PIK3CA—ovarian cancer	3.09e-07	0.000181	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—KRAS—ovarian cancer	3.07e-07	0.00018	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PIK3CA—ovarian cancer	3.07e-07	0.00018	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	3.01e-07	0.000176	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CG—ovarian cancer	3e-07	0.000176	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TP53—ovarian cancer	2.99e-07	0.000175	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CG—ovarian cancer	2.98e-07	0.000174	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TP53—ovarian cancer	2.97e-07	0.000174	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.93e-07	0.000172	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	2.93e-07	0.000172	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TP53—ovarian cancer	2.91e-07	0.00017	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—STAT3—ovarian cancer	2.9e-07	0.00017	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NRAS—ovarian cancer	2.9e-07	0.000169	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CD—ovarian cancer	2.87e-07	0.000168	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—HRAS—ovarian cancer	2.86e-07	0.000167	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—HRAS—ovarian cancer	2.84e-07	0.000166	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	2.82e-07	0.000165	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.8e-07	0.000164	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—HRAS—ovarian cancer	2.78e-07	0.000163	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	2.77e-07	0.000162	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IL6—ovarian cancer	2.74e-07	0.00016	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TP53—ovarian cancer	2.73e-07	0.00016	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.72e-07	0.000159	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL6—ovarian cancer	2.72e-07	0.000159	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MYC—ovarian cancer	2.7e-07	0.000158	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—TYMS—ovarian cancer	2.67e-07	0.000156	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL6—ovarian cancer	2.66e-07	0.000156	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CA—ovarian cancer	2.65e-07	0.000155	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CD—ovarian cancer	2.64e-07	0.000154	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	2.64e-07	0.000154	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EGFR—ovarian cancer	2.64e-07	0.000154	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CD—ovarian cancer	2.62e-07	0.000153	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—HRAS—ovarian cancer	2.61e-07	0.000153	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—AKT1—ovarian cancer	2.52e-07	0.000148	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—AKT1—ovarian cancer	2.51e-07	0.000147	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CB—ovarian cancer	2.5e-07	0.000146	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CA—ovarian cancer	2.5e-07	0.000146	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL6—ovarian cancer	2.5e-07	0.000146	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—KRAS—ovarian cancer	2.49e-07	0.000146	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—AKT1—ovarian cancer	2.46e-07	0.000144	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.44e-07	0.000143	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—AKT1—ovarian cancer	2.31e-07	0.000135	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CB—ovarian cancer	2.3e-07	0.000135	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	2.29e-07	0.000134	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CB—ovarian cancer	2.28e-07	0.000133	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TP53—ovarian cancer	2.22e-07	0.00013	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTEN—ovarian cancer	2.16e-07	0.000126	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—AKT1—ovarian cancer	2.16e-07	0.000126	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CAV1—ovarian cancer	2.16e-07	0.000126	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—HRAS—ovarian cancer	2.12e-07	0.000124	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTEN—ovarian cancer	2.11e-07	0.000123	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—AKT1—ovarian cancer	2.04e-07	0.00012	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL6—ovarian cancer	2.03e-07	0.000119	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTEN—ovarian cancer	1.99e-07	0.000116	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTEN—ovarian cancer	1.97e-07	0.000115	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.96e-07	0.000115	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—AKT1—ovarian cancer	1.87e-07	0.000109	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.73e-07	0.000101	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CA—ovarian cancer	1.52e-07	8.92e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.5e-07	8.8e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.49e-07	8.71e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.4e-07	8.21e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.39e-07	8.13e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTEN—ovarian cancer	1.3e-07	7.6e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—AKT1—ovarian cancer	1.25e-07	7.29e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—AKT1—ovarian cancer	1.22e-07	7.11e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—AKT1—ovarian cancer	1.15e-07	6.7e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—AKT1—ovarian cancer	1.14e-07	6.65e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CA—ovarian cancer	9.17e-08	5.36e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—AKT1—ovarian cancer	7.49e-08	4.38e-05	CbGpPWpGaD
